“Microalbuminuria as a potential novel cardiovascular biomarker in patients with COPD.” Ciro Casanova and Bartolome R. Celli. Eur Respir J 2014; 43: 951–953.


Source: Eur Respir J 2014; 43: 1825
Journal Issue: June
Disease area: Airway diseases

Full text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
“Microalbuminuria as a potential novel cardiovascular biomarker in patients with COPD.” Ciro Casanova and Bartolome R. Celli. Eur Respir J 2014; 43: 951–953.. Eur Respir J 2014; 43: 1825

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
“Cardiovascular disease and COPD: dangerous liaisons?” Klaus F. Rabe, John R. Hurst and Samy Suissa. Eur Respir Rev 2018; 27: 180057.
Source: Eur Respir Rev, 27 (150) 185057; 10.1183/16000617.5057-2018
Year: 2018


“RESPIRE: breathing new life into bronchiectasis.” Sanjay H. Chotirmall and James D. Chalmers. Eur Respir J 2018; 51: 1702444.
Source: Eur Respir J, 51 (2) 1752444; 10.1183/13993003.52444-2017
Year: 2018


“Exercise pulmonary haemodynamics: a test in search of purpose.” J. Gerry Coghlan and Harm Jan Bogaard. Eur Respir J 2016; 47: 1315–1317.
Source: Eur Respir J 2016; 48: 285
Year: 2016


“Number needed to treat: enigmatic results for exacerbations in COPD.” Samy Suissa. Eur Respir J 2015; 45: 875–878.
Source: Eur Respir J, 51 (6) 1452165; 10.1183/13993003.52165-2014
Year: 2018


“Do bacteria have a role in asthma development?” J. Armann and E. von Mutius. Eur Respir J 2010; 36: 469–471.
Source: Eur Respir J, 54 (1) 1050414; 10.1183/13993003.50414-2010
Year: 2019


“Health consequences associated with frequent wheezing in adolescents without asthma diagnosis.” K. Yeatts, K. Johnston Davis, D. Peden and C. Shy. Eur Respir J 2003; 22: 781–786.
Source: Eur Respir J 2015; 46: 1532
Year: 2015


“Alveolar macrophages carbon load: a marker of exposure?” Chinedu Nwokoro, Rossa Brugha and Jonathan Grigg. Eur Respir J 2013; 41: 763.
Source: Eur Respir J 2013; 42: 295
Year: 2013


“The therapy of idiopathic pulmonary fibrosis: what is next?” Vivien Somogyi, Nazia Chaudhuri, Sebastiano Emanuele Torrisi, et al. Eur Respir Rev 2019; 28: 190021.
Source: Eur Respir Rev, 28 (153) 195021; 10.1183/16000617.5021-2019
Year: 2019


“Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis.” Bridget F. Collins and Ganesh Raghu. Eur Respir Rev 2019; 28: 190022.
Source: Eur Respir Rev, 28 (154) 195022; 10.1183/16000617.5022-2019
Year: 2019


“Metabolic dysfunction in pulmonary hypertension: from basic science to clinical practice.” Stephen Y. Chan and Lewis J. Rubin. Eur Respir Rev 2017; 26: 170094.
Source: Eur Respir Rev, 27 (147) 175094; 10.1183/16000617.5094-2017
Year: 2018


“Central sleep apnoea and periodic breathing in heart failure: prognostic significance and treatment options.” Winfried Randerath, Oana Deleanu, Sophia Schiza and Jean-Louis Pepin. Eur Respir Rev 2019; 28: 190084.
Source: Eur Respir Rev, 28 (154) 195084; 10.1183/16000617.5084-2019
Year: 2019


“Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis.” Yasuhiro Kondoh, Vincent Cottin and Kevin K. Brown. Eur Respir Rev 2017; 26: 170050.
Source: Eur Respir Rev, 27 (148) 175050; 10.1183/16000617.5050-2017
Year: 2018


“Reproducibility of 6-minute walking test in patients with COPD”. N.A. Hernandes, E.F.M. Wouters, K. Meijer, J. Annegarn, F. Pitta and M.A. Spruit. Eur Respir J 2011; 38: 261–267.
Source: Eur Respir J 2012; 40: 1583
Year: 2012


“Triple therapy in idiopathic pulmonary fibrosis: an alarming press release.” A.U. Wells, J. Behr, U. Costabel, V. Cottin and V. Poletti. Eur Respir J 2012; 39: 805–806.
Source: Eur Respir J 2012; 39: 1552
Year: 2012


“Asthma inhaler adherence determinants in adults: systematic review of observational data.” Alexandra L. Dima, Gimena Hernandez, Oriol Cunillera, Montserrat Ferrer, Marijn de Bruin and the ASTRO-LAB group. Eur Respir J 2015; 45: 994–1018.
Source: Eur Respir J 2016; 47:1892
Year: 2016


“Functional ageing in fibrotic interstitial lung disease: the impact of frailty on adverse health outcomes.” Sabina A. Guler, Joanne M. Kwan, Janice M. Leung, Nasreen Khalil, Pearce G. Wilcox and Christopher J. Ryerson. Eur Respir J 2020; 55: 1900647.
Source: Eur Respir J, 55 (3) 1950647; 10.1183/13993003.50647-2019
Year: 2020



“Is bronchiectasis really a disease?” Michal Shteinberg, Patrick A. Flume and James D. Chalmers. Eur Respir Rev 2020; 29: 190051.
Source: Eur Respir Rev, 29 (155) 195051; 10.1183/16000617.5051-2019
Year: 2020


“Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis.” Vincent Cottin and Toby Maher. Eur Respir Rev 2015; 24: 58–64.
Source: Eur Respir Rev 2015; 24: 545
Year: 2015


“Umeclidinium in patients with COPD: a randomised, placebo-controlled study.” Roopa Trivedi, Nathalie Richard, Rashmi Mehta and Alison Church. Eur Respir J 2014; 43: 72–81.
Source: Eur Respir J 2014; 44: 555
Year: 2014


“Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis.” Michael Kreuter, Marlies S. Wijsenbeek, Martina Vasakova, Paolo Spagnolo, Martin Kolb, Ulrich Costabel, Derek Weycker, Klaus-Uwe Kirchgaessler and Toby M. Maher. Eur Respir J 2016; 47: 1776–1784.
Source: Eur Respir J 2016; 48: 593
Year: 2016